Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer

NCT04940325 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Lung Cancer
Advanced Non Small Cell Lung Cancer
Unresectable Non-small Lung Cancer

Interventions

DRUG: DS-1062a

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Collaborators

[object Object]